Moderna Faces Challenges Beyond the Covid Vaccine. Its Stock Is Still a Buy for the Long Term.

In 2019, four pharmaceutical giants shared virtually all of the $33 billion worth of vaccine revenue earned worldwide. The pandemic has upended the vaccine business. Moderna has sold or contracted to ...